Personalized Obesity and Lipid-Related Metabolic Disorder Prevention and Treatment System
Legal Citation
Summary of the Inventive Concept
A next-generation system for personalized prevention and treatment of obesity and lipid-related metabolic disorders, leveraging machine learning, genomics, and precision medicine to deliver tailored therapeutic regimens and improve treatment outcomes.
Background and Problem Solved
The original patent disclosed a composition for preventing or treating obesity or lipid-related metabolic disorders using a steroid sulfatase inhibitor. However, the existing approach has limitations, including a one-size-fits-all treatment strategy and lack of personalization. The new inventive concept addresses these limitations by integrating machine learning, genomics, and precision medicine to create a personalized prevention and treatment system.
Detailed Description of the Inventive Concept
The system comprises a machine learning module trained on a database of genomic, epigenomic, and environmental factors to predict individualized therapeutic efficacy of a steroid sulfatase inhibitor. A delivery module administers a tailored dosage of the inhibitor based on the prediction. The system also includes a genomics-based diagnostic module for identifying genetic predispositions to obesity and lipid-related metabolic disorders, and a therapeutic module for administering a customized regimen of the inhibitor and other synergistic compounds. Additionally, the system incorporates wearable devices for real-time monitoring of metabolic profiles, enabling dynamic adjustments to the treatment regimen.
Novelty and Inventive Step
The new claims introduce a paradigm shift by integrating machine learning, genomics, and precision medicine to create a personalized prevention and treatment system. The inventive concept's novelty lies in its ability to predict individualized therapeutic efficacy, dynamically adjust treatment regimens, and provide a tailored approach to preventing and treating obesity and lipid-related metabolic disorders.
Alternative Embodiments and Variations
Alternative embodiments may include using different machine learning algorithms, incorporating additional data sources such as medical imaging or electronic health records, or developing novel nanoparticle-based delivery systems for the steroid sulfatase inhibitor. Variations may also include adapting the system for use in different populations or for treating other related disorders.
Potential Commercial Applications and Market
The personalized obesity and lipid-related metabolic disorder prevention and treatment system has significant commercial potential in the healthcare and pharmaceutical industries. The system's ability to provide tailored therapeutic regimens and improve treatment outcomes positions it for widespread adoption in clinical settings and potential partnerships with pharmaceutical companies.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, metabolic disorder treatment, precision medicine, with expertise in machine learning, genomics, and personalized therapeutic interventions
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in biotechnology, pharmaceutical sciences, or biomedical engineering, possessing knowledge of steroid sulfatase inhibitors, machine learning techniques, and personalized medical approaches
Obviousness Rationale
A PHOSITA would recognize that the PTD represents a predictable extension of the source patent's core invention by applying known precision medicine techniques to the existing steroid sulfatase inhibitor treatment methodology. The integration of machine learning, genomic analysis, and personalized dosing represents a logical progression of treatment optimization strategies already implied in the original patent's therapeutic approach. The variations demonstrate standard engineering design choices that would be apparent to a skilled practitioner seeking to improve treatment efficacy and patient outcomes.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,533 |
|---|---|
| Title | Composition for preventing or treating obesity or lipid-related metabolic disorders |
| Assignee(s) | Nexyon Biotech Co., Ltd. |